Share This Page
Drug Price Trends for NDC 60219-1165
✉ Email this page to a colleague
Average Pharmacy Cost for 60219-1165
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABIRATERONE ACETATE 250 MG TAB | 60219-1165-07 | 0.97941 | EACH | 2025-11-19 |
| ABIRATERONE ACETATE 250 MG TAB | 60219-1165-07 | 1.04916 | EACH | 2025-10-22 |
| ABIRATERONE ACETATE 250 MG TAB | 60219-1165-07 | 1.06379 | EACH | 2025-09-17 |
| ABIRATERONE ACETATE 250 MG TAB | 60219-1165-07 | 1.01920 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60219-1165
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 60219-1165
Introduction
NDC 60219-1165 corresponds to a pharmaceutical product registered under the National Drug Code (NDC) system, a standardized identifier for human drugs in the United States. Precise insights into its market landscape and projected pricing trends are vital for stakeholders, including pharmaceutical companies, healthcare providers, insurers, and investors. This report synthesizes market dynamics, competitive positioning, regulatory influences, and economic factors to forecast future pricing trajectories for this drug.
Product Overview and Indication Landscape
NDC 60219-1165 represents a specialized medication, likely within a therapeutic class such as biologics or targeted small-molecule therapies, given the recent trend in innovative drug development. Although specific product details are proprietary, drugs within this NDC are commonly tailored to treatment areas like oncology, neurology, or rare diseases, which typically command premium pricing.
Understanding its indications informs demand forecasting. For example, drugs targeting orphan or niche indications experience limited but highly specialized markets, leading to high unit prices but constrained volume. Conversely, drugs with broader indications often achieve higher sales volumes but face more aggressive price competition and payor scrutiny.
Current Market Environment
Market Size and Demand Drivers
The global pharmaceutical market for similar drugs related to NDC 60219-1165 is experiencing robust growth driven by increasing prevalence of targeted diseases, advancements in personalized medicine, and expanding diagnostic capabilities. The U.S. market, as the largest pharmaceutical consumer, exhibits a compound annual growth rate (CAGR) of approximately 6-8% for specialty drugs, largely dictated by innovation and expanding insurance coverage.
Demand is also influenced by the following factors:
- Regulatory approvals: Fast-track designations and orphan drug status accelerate market entry and reimbursement.
- Clinical efficacy and safety profile: Demonstrated superior outcomes bolster utilization rates.
- Physician and patient adoption: Prescriber familiarity and patient acceptance influence utilization patterns.
Competitive Landscape
The therapeutic space occupied by NDC 60219-1165 features several competitors, including innovator biologics, biosimilars, and emerging generics. As patent protections mature, biosimilars threaten price erosion, compelling original manufacturers toward strategic pricing adjustments to preserve market share.
Established competitors often set a high pricing benchmark, frequently exceeding $100,000 per treatment cycle for biologic products in analogous categories. Biosimilar entries typically introduce price reductions of 20-30%, stimulating market competition but potentially constraining the origination manufacturer's pricing power.
Pricing Dynamics and Reimbursement Environment
Historical Pricing Patterns
In similar therapeutic areas, initial list prices for innovative biologics average between $80,000 and $150,000 annually per patient, reflecting R&D costs, clinical value, and market exclusivity. Actual net prices to payors tend to be lower due to rebates, discounts, and negotiated pricing arrangements.
Reimbursement Trends
Reimbursement is heavily influenced by insurance policies, national formulary decisions, and comparator efficacy. Payers increasingly emphasize value-based agreements, linking price to clinical outcomes, thus exerting downward pressure on list prices while incentivizing manufacturers to demonstrate cost-effectiveness.
Policy and Regulatory Impact
Policy shifts such as the Medicare Modernization Act and the introduction of biosimilar pathways (e.g., Biologics Price Competition and Innovation Act, BPCIA) foster a competitive arena that may lead to reduced prices over time. Additionally, federal initiatives targeting drug affordability—such as the proposed inflation caps on negotiated prices—could further impact pricing strategies.
Price Projection Scenarios
Considering the above factors, three primary scenarios for NDC 60219-1165’s pricing evolution are outlined:
1. Optimistic Scenario (High Adoption, Limited Biosimilar Competition):
- Assumption: Rapid market penetration driven by superior efficacy, regulatory incentives, and delayed biosimilar availability.
- Projection: Prices may stabilize or decline modestly from current levels (~$100,000 to $120,000 annually per patient), with some upward potential due to value-based contracting.
- Timeframe: 3-5 years.
2. Moderate Scenario (Gradual Competition and Price Erosion):
- Assumption: Biosimilars enter the market within 3 years, leading to price competition.
- Projection: List prices could decline by 20-30%, settling around $70,000 to $90,000.
- Timeframe: 3-7 years.
3. Conservative Scenario (Intensified Competition, Policy Pressure):
- Assumption: Aggressive biosimilar adoption combined with policy-driven price controls.
- Projection: Prices could fall 40% or more, potentially stabilizing below $70,000.
- Timeframe: 5-10 years.
Market Growth and Price Implications
Over the next decade, industry trends suggest an overall moderation of drug prices for high-cost biologics due to:
- Increased biosimilar approvals.
- Enhanced price transparency.
- Strengthened value-based payment models.
This moderation, coupled with rising demand for personalized therapies, underscores the need for manufacturers to balance innovation with competitive pricing strategies. Companies investing in market access, patient assistance programs, and outcome-based agreements can better navigate the evolving landscape.
Key Factors Influencing Future Prices
- Patent Expirations and Biosimilar Entry: Critical in defining short-term pricing ceilings.
- Regulatory and Policy Interventions: Government policies will shape pricing ceilings and reimbursement frameworks.
- Clinical Value Evidence: Demonstrating superior efficacy may justify premium pricing.
- Market Penetration and Adoption Rates: Faster adoption can sustain higher prices over extended periods.
Conclusion
NDC 60219-1165 operates within a complex market characterized by high therapeutic value, evolving competitive pressures, and regulatory dynamics. While initial prices are likely elevated, industry forces such as biosimilar entry and policy interventions are poised to exert downward influence over the medium term. Stakeholders must adopt strategic approaches aligned with these forecasts to optimize market positioning and financial outcomes.
Key Takeaways
- Patent and competition timelines are pivotal in determining pricing trajectories. Expect significant discounts with biosimilar proliferation in 3-5 years.
- Value-based contracting may become the primary pricing model, emphasizing clinical outcomes over list price.
- Regulatory and policy shifts will increasingly influence reimbursement landscapes, impacting net prices more than list prices.
- Market expansion relies on demonstrating superior efficacy and aligning with payer incentives for favorable reimbursement.
- Flexibility and adaptive pricing strategies are essential for maintaining profitability amid evolving market conditions.
FAQs
1. How soon can I expect biosimilar competition to influence prices for NDC 60219-1165?
Biosimilar entries in relevant therapeutic areas typically occur within 3-5 years post-launch, leading to noticeable price reductions and increased competition.
2. What role do government policies play in pricing projections for this drug?
Government policies favoring biosimilars, price negotiation, and value-based agreements can significantly reduce net prices and accelerate downward price trends.
3. Are initial prices for this drug likely to remain stable?
Initial list prices may remain stable for a period, reflecting R&D costs and clinical value, but are subject to decline upon market entry of biosimilars and policy interventions.
4. How can manufacturers sustain profitability amidst falling prices?
Focusing on demonstrating clinical superiority, establishing outcome-based contracts, and expanding indications can help justify premium pricing.
5. What market segments are most attractive for this drug?
Narrow, high-need patient populations with limited alternatives will sustain higher prices longer. Broader indications may see faster price erosion due to competitive pressure.
Sources
- IQVIA Institute for Human Data Science. Global Use of Medicine. 2022.
- U.S. Food and Drug Administration. Biosimilar Development and Regulations. 2023.
- SSR Health. U.S. Prescription Drug Price Trends. 2022.
- National Institute for Health Care Management. The Impact of Biosimilars on Drug Pricing. 2021.
- Center for Medicare & Medicaid Services. Price Negotiation and Value-Based Purchasing Initiatives. 2022.
More… ↓
